Réactifs et instruments pour l'immunologie, la biologie cellulaire et la biologie moléculaire.
 
> Cidofovir [113852-37-2]

Cidofovir [113852-37-2]

Imprimer Imprimer
Identifiez-vous

Référence HY-17438-10mg

Conditionnement : 10mg

Marque : MedChemExpress

Contactez votre distributeur local :


Téléphone : +1 850 650 7790

Cidofovir (GS 0504) is an acyclic monophosphate nucleotide analogue and CMV inhibitor with antiviral activity. Cidofovir inhibits cytomegalovirus (CMV) replication by selectively inhibiting viral DNA polymerase. Cidofovir induces apoptosis and can be used in studies of AIDS cytomegalovirus retinitis, herpes, and cancer. Cidofovir also has anti-orthopoxvirus and anti-variola activities.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Cidofovir Chemical Structure

Cidofovir Chemical Structure

CAS No. : 113852-37-2

This product is a controlled substance and not for sale in your territory.

Based on 2 publication(s) in Google Scholar

Other Forms of Cidofovir:

  • Cidofovir dihydrate Obtenir un devis
Description

Cidofovir (GS 0504) is an acyclic monophosphate nucleotide analogue and CMV inhibitor with antiviral activity. Cidofovir inhibits cytomegalovirus (CMV) replication by selectively inhibiting viral DNA polymerase. Cidofovir induces apoptosis and can be used in studies of AIDS cytomegalovirus retinitis, herpes, and cancer[1][3]. Cidofovir also has anti-orthopoxvirus and anti-variola activities[4].

In Vitro

Cidofovir (5-100 μM, 72 hours) has antiviral activity against feline herpesvirus type-1 (FHV-1) with an IC50 of 11 μM, and can reduce Crandell-Reese feline kidney cell counts in a dose-dependent manner[1].
? Cidofovir (10-1000 μM, 24-120 hours) can reduce cancer cell viability and induces apoptosis[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cidofovir Related Antibodies

Cell Cytotoxicity Assay[1]

Cell Line: Crandell-Reese feline kidney(CRFK) cells
Concentration: 10-100 μM
Incubation Time: 72 hours
Result: Reduced CRFK cells by 9.1%.

Cell Viability Assay[3]

Cell Line: Caco-2, FTC-133, HeLa, Hep-G2, MDA-MB-231, NCI-H1975 and PC-3 cells
Concentration: 10-1000 μM
Incubation Time: 24, 48, 72, 96, 120 hours
Result: Resulted in a gradual decrease in tumor cell viability with time and concentration increasing and inhibited the number of FTC-133 cell clones by about 55% at 100 μM comparing to the untreated group.

Apoptosis Analysis[3]

Cell Line: FTC-133 cells
Concentration: 100 μM
Incubation Time: 96 hours
Result: Showed a significant increase in the expression of pro-apoptotic proteins, such as cytochrome c, phospho-p53 (S15) and caspase-3 by 130%, 49%, and 46%, respectively while the anti-apoptotic protein Bcl-x decreased significantly by 57% comparing to the untreated cells.
In Vivo

Cidofovir (subcutaneous injection, 100 mg/kg, 3-6 days interval, 21 days) is highly protective against death from cowpox virus (CPV) infection at high doses in female weanling BALB/c mice[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female weanling BALB/c mice infected with cowpox virus (CPV)[2]
Dosage: 100 mg/kg
Administration: Subcutaneous injection; 3-6 days interval; 21 days
Result: Prevented 80-100% of mouse deaths when administered on the first 4-3 days before infection.
Protected 35-50% of mice when administered on the fourth day after infection, and 10-20% when administered on the sixth day.
Essai clinique
Masse moléculaire

279.19

Formule

C8H14N3O6P
CAS No.

113852-37-2
Appearance

Solid

Color

White to off-white

SMILES

OC[C@@H](OCP(O)(O)=O)CN1C=CC(N)=NC1=O
Structure Classification
  • Others
Initial Source
  • Endogenous metabolite
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvant et solubilité
In Vitro: 

H2O : 3.33 mg/mL (11.93 mM; Need ultrasonic)

DMSO : < 1 mg/mL (insoluble or slightly soluble)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.5818 mL 17.9090 mL 35.8179 mL
5 mM 0.7164 mL 3.5818 mL 7.1636 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Calculateur de molarité

  • Calculateur de dilution

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  PBS

    Solubility: 4.55 mg/mL (16.30 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Pureté et documentation

Purity: 99.74%

COA (252 KB) HNMR (260 KB) CNMR (260 KB) LCMS (93 KB)

Instruction de manipulation (2659 KB)
Références

  • [1]. David J Maggs, et al. In vitro efficacy of ganciclovir, cidofovir, penciclovir, foscarnet, idoxuridine, and acyclovir against feline herpesvirus type-1. Am J Vet Res. 2004 Apr;65(4):399-403.  [Content Brief]

    [2]. M Bray, et al. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J Infect Dis. 2000 Jan;181(1):10-9.  [Content Brief]

    [3]. Simona Catalani, et al. Reduced cell viability and apoptosis induction in human thyroid carcinoma and mesothelioma cells exposed to cidofovir. Toxicol In Vitro. 2017 Jun;41:49-55.  [Content Brief]

    [4]. Robert O Baker, et al. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res. 2003 Jan;57(1-2):13-23.  [Content Brief]

  • [1]. David J Maggs, et al. In vitro efficacy of ganciclovir, cidofovir, penciclovir, foscarnet, idoxuridine, and acyclovir against feline herpesvirus type-1. Am J Vet Res. 2004 Apr;65(4):399-403.

    [2]. M Bray, et al. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J Infect Dis. 2000 Jan;181(1):10-9.

    [3]. Simona Catalani, et al. Reduced cell viability and apoptosis induction in human thyroid carcinoma and mesothelioma cells exposed to cidofovir. Toxicol In Vitro. 2017 Jun;41:49-55.

    [4]. Robert O Baker, et al. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res. 2003 Jan;57(1-2):13-23.

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
H2O 1 mM 3.5818 mL 17.9090 mL 35.8179 mL 89.5448 mL
5 mM 0.7164 mL 3.5818 mL 7.1636 mL 17.9090 mL
10 mM 0.3582 mL 1.7909 mL 3.5818 mL 8.9545 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Cidofovir Related Classifications

  • Anti-infection Apoptosis Cell Cycle/DNA Damage Metabolic Enzyme/Protease
  • CMV Apoptosis DNA/RNA Synthesis Orthopoxvirus Endogenous Metabolite
Help & FAQs

Keywords:

Cidofovir113852-37-2GS 0504 HPMPC (S)-HPMPCGS0504GS-0504CMVApoptosisDNA/RNA SynthesisOrthopoxvirusEndogenous MetaboliteCytomegalovirusantiviralcytomegalovirusretinitisherpescancerInhibitorinhibitorinhibit

Vous serez peut-être également intéressé par les produits suivants :



Référence
Description
Cond.
Prix HT
A8542-50mg
Triflurdine (Viroptic) [70-00-8]
 50mg 
B1089-5mg
CMX001 [444805-28-1]
 5mg